BEN 34712
Alternative Names: BEN-34712Latest Information Update: 26 Sep 2024
At a glance
- Originator BenevolentAI
- Developer BenevolentAI; University of Sheffield
- Class Neuroprotectants
- Mechanism of Action Retinoic acid receptor alpha agonists; Retinoic acid receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis